Alpha Cognition (ACOG) Stock Fundamentals, Analysis & Risk Signals

Health score, price, valuation, risk signals, and key metrics at a glance.

Alpha Cognition

NasdaqCM•Healthcare•Biotechnology

$9.24+0.84(0.10%)Market open

Market Cap

$201.19M

P/S

13.2x

P/B

3.8x

Alpha Cognition Inc., a biopharmaceutical company, engages in the development of treatments for patients suffering from neurodegenerative diseases in the United States and Canada. The company's commercial development program includes ZUNVEYL oral tablet formulation for treating Alzheimer's disease. Its pre-clinical development programs comprise ZUNVEYL in combination with memantine for the treatment of moderate-to-severe Alzheimer's disease; ALPHA-1062 sublingual formulation; ALPHA-1062 intranasal formulation for the treatment of cognitive impairment with mild traumatic brain injury; and ALPHA-0602, ALPHA-0702, and ALPHA-0802 programs for the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis disease and spinal muscular atrophy. Alpha Cognition Inc. was founded in 2000 and is headquartered in Grapevine, Texas.

How this company scores

AverageMetricSide Score: 55/100

Strongest: Growth (20/25); weakest: Cash & Earnings Quality (6/25).

Profitability14/25

Growth20/25

Balance Sheet & Red Flags15/25

Cash & Earnings Quality6/25

Strengths

Growing revenueInterest easily coveredConsistent growthNet cash position

Valuation vs. 5-year range

Today's multiple positioned against its own trailing range — a visual premium/discount check.

P/S · 13.2x5y range 10.7x – 32.6x

Currently near its 6-quarter median.

P/B · 3.8x5y range 1.0x – 4.7x

Currently above its 7-quarter median.

Watch items

Data-driven signals worth keeping an eye on across the last 8 quarters

High Risk

Margin Pressure

Red Flag

The company posted negative operating margins in recent quarters — core operations are unprofitable.

Earnings Quality

Red Flag

Free cash flow has been negative in 8 of the last 8 quarters — earnings are not translating to cash.

Price & Volume

Market Cap $201.19M

Metrics at a Glance

as of June 2026

Revenue & Profit

Revenue, EBITDA, operating income, net income, EPS, and shares

TTM Revenue: $15.26M
Q. Revenue: $6.09M
TTM EBITDA: $-29.00M
TTM Op. Income: $-29.09M
Q. Op. Income: $-7.76M
TTM Net Income: $-23.44M
Q. Net Income: $-8.79M
EPS: $-0.4
Shares Out.: $21.77M

$15.26M in TTM revenue grew 232.7% YoY, reaching $6.09M last quarter. TTM EBITDA of $-29.00M and TTM operating income of $-29.09M show growth is flowing through to the bottom line. However, net income is negative at $23.44M — growth is not yet reaching the bottom line. Across the last 8 quarters, TTM revenue has risen for 6 consecutive quarters — an improving trend.

Margins

Gross, EBITDA, operating, and net margin trends

Gross Margin: 93.6%
EBITDA Margin: -126.1%
Op. Margin: -127.3%
Net Margin: -144.3%

Op. margin of -127.3% is up 218.8% YoY — cost efficiency is improving. Net margin at -144.3% and gross margin of 93.6% show how much of each revenue dollar survives to profit. Across the last 8 quarters, operating margin has risen for 2 consecutive quarters — an improving trend.

Price Ratios

P/E, P/S, P/B, EV/EBITDA, FCF yield, and earnings yield

P/E Ratio: N/A
P/S Ratio: 13.2x
P/B Ratio: 3.8x

P/S of 13.2x and P/B of 3.8x. P/S is high, meaning growth expectations are priced in.

Assets & Liabilities

Total assets, cash, debt, book value, and leverage

Total Assets: $64.52M
Cash: $41.38M
Long-Term Debt: N/A
Book Value: $52.96M
D/E Ratio: N/A
Debt/EBITDA: N/A

Cash Flow

Operating cash flow, free cash flow, FCF margin, and earnings quality

Op. Cash Flow: $-6.86M
TTM Free Cash Flow: $-31.18M
FCF Margin: -204.3%
FCF / Net Income: 1.3

TTM FCF of $-31.18M on $-6.86M in operating cash flow. The FCF / Net Income ratio of 1.3x means free cash flow covers net income — earnings are backed by cash. Across the last 8 quarters, free cash flow has fallen for 6 consecutive quarters — a weakening trend.